QUEBEC CITY, Dec. 22, 2014 /CNW Telbec/ - Opsens Inc. ("Opsens") (TSXV: OPS) is pleased to announce the first use of its Fractional Flow Reserve
("FFR") products in several patients during the 21st Kamakura Live Demonstration Course 2014 (www.kamakuralive.net) in Yokohama (Japan) by Dr. Shigeru Saito. The OptoWire and OptoMonitor
are Opsens' products for FFR measurements to optimize the diagnosis and
guide the therapy in patients with coronary artery disease.
"The Kamakura Live Demonstration Course is an event to introduce to
Japanese cardiologists new medical devices and practices intended to
improve the treatment and the health of patients. Opsens' FFR products
fit very well with this vision given the important benefits that they
provide for efficiency and effectiveness in the treatment of coronary
lesions. It was a great experience for me to demonstrate this new FFR
system and I intend to continue using it", said Dr. Saito.
"Opsens' team is honoured to have their products used by Dr. Saito in
the prestigious Kamakura Live Demonstration Course. The credibility of
Dr. Saito and this event will be an asset to our marketing activities
in Japan as well as around the world. Opsens is also pleased to
announce that we have obtained a new regulatory approval in Japan for
the latest generation of OptoWire. With this new generation FFR wire,
we are now initiating our limited market launch with selected hospitals
in Japan", said Louis Laflamme, President and CEO of Opsens.
Opsens aims at becoming a key player in the guidewire FFR market with
the OptoWire, a nitinol-based optical guidewire for FFR. The OptoWire
provides intra-coronary blood pressure measurements with unique,
patented optical pressure guidewire technologies. It is immune to
adverse effects related to blood contact, and allows easy and reliable
connectivity that leads to reliable FFR measurements in extended
conditions of usage. The OptoWire is also designed to provide
cardiologists with a guidewire delivering optimized performances to
navigate coronary arteries and reach blockages with ease. Based on
industry sources, the FFR market represented over US$250 million in
sales in 2013 and is expected to reach US$1 billion in the medium-term.
Opsens is confident that it is well positioned to capitalize on this
significant growth opportunity.
About Opsens Inc. (www.opsensmedical.com or www.opsens.com)
The Company focuses mainly on two large and growing markets: the
interventional cardiology and the oil and gas industry. In
interventional cardiology, Opsens offers advanced optical based
pressure guidewire that aims at improving the clinical outcome of
patients with coronary artery disease. Opsens also develops,
manufactures and installs innovative fibre optic sensing solutions for
critical applications such as the monitoring of oil wells and other
demanding industrial applications.
Forward-looking statements contained in this press release involve known
and unknown risks, uncertainties and other factors that may cause
actual results, performance and achievements of Opsens to be materially
different from any future results, performance or achievements
expressed or implied by the said forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE OPSENS INC.
Thierry Dumas, CPA, CA, Chief Financial Officer, 418.682.9996; Louis Laflamme, CPA, CA, Chief Executive Officer, 418.682.9996
Copyright CNW Group 2014